Clovis Oncology Announces Positive Outcome in European Opposition Proceeding Related to Rubraca® Business Wire
Clovis Oncology, Inc. (NASDAQ:CLVS) announced today after opposition proceedings at The Hague, Netherlands, that the European Patent Office upheld cla.
Source:: Oakland, California News By Google News